Log in to save to my catalogue

AB0528 BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SP...

AB0528 BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SP...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2821978159

AB0528 BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT

About this item

Full title

AB0528 BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT

Publisher

Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1461-1462

Language

English

Formats

Publication information

Publisher

Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

BackgroundBelimumab (BLM) is a recombinant human IgG-1λ monoclonal antibody that inhibits B-cell activating factor. It is commonly used for treatment of systemic lupus erythematosus (SLE) patients with inadequate control to first-line treatments and inability to taper GC daily dose to acceptable levels. More recently it has been approved for patien...

Alternative Titles

Full title

AB0528 BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2821978159

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2821978159

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2023-eular.3003

How to access this item